Patrik Bjärterot

Patrik Bjärterot

Auto-generated profile, based on publicly available information

Patrik Bjärterot

Department of Pharmaceutical Biosciences, Spatial Mass Spectrometry, Science for Life Laboratory, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Nature Biotechnology
Verified
Journal Article
Open access
PDF file
MVMarco Vicari
Marco Vicari
RMReza Mirzazadeh
Reza Mirzazadeh
ANAnna Nilsson
Anna Nilsson
RSReza Shariatgorji
Reza Shariatgorji
PBPatrik Bjärterot
Patrik Bjärterot
JLJoakim Lundeberg
Joakim Lundeberg
We present a spatial omics approach that combines histology, mass spectrometry imaging and spatial transcriptomics to facilitate precise measurements of mRNA transcripts and low-molecular-weight metabolites across tissue regions. The workflow is compatible with commercially available Visium glass slides. We demonstrate the potential of our method using mouse and human brain samples in the context of dopamine and Parkinson’s disease.

26 July 2023 in npj Parkinson's Disease
Verified
Journal Article
Open access
PDF file
IKIbrahim Kaya
Ibrahim Kaya
ANAnna Nilsson
Anna Nilsson
DLDominika Luptáková
Dominika Luptáková
YHYachao He
Yachao He
TVTheodosia Vallianatou
Theodosia Vallianatou
PAPer E. Andrén
Per E. Andrén
Metabolism of MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) to the neurotoxin MPP+ in the brain causes permanent Parkinson’s disease-like symptoms by destroying dopaminergic neurons in the pars compacta of the substantia nigra in humans and non-human primates. However, the complete molecular pathology underlying MPTP-induced parkinsonism remains poorly understood. We used dual polarity matrix-assisted laser desorption/ionization mass spectrometry imaging to thoroughly image numerous glycerophospholipids and sphingolipids in coronal brain tissue sections of MPTP-lesioned and control non-human primate brains (Macaca mulatta). The results revealed specific distributions of several sulfatide lipid molecules based on chain-length, number of double bonds, and importantly, hydroxylation stage. More specifically, certain long-chain hydroxylated sulfatides with polyunsaturated chains in the molecular structure were depleted within motor-related brain regions in the MPTP-lesioned animals, e.g., external and internal segments of globus pallidus and substantia nigra pars reticulata. In contrast, certain long-chain non-hydroxylated sulfatides were found to be elevated within the same brain regions. These findings demonstrate region-specific dysregulation of sulfatide metabolism within the MPTP-lesioned macaque brain. The depletion of long-chain hydroxylated sulfatides in the MPTP-induced pathology indicates oxidative stress and oligodendrocyte/myelin damage within the pathologically relevant brain regions. Hence, the presented findings improve our current understanding of the molecular pathology of MPTP-induced parkinsonism within primate brains, and provide a basis for further research regarding the role of dysregulated sulfatide metabolism in PD.

27 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
MVMarco Vicari
Marco Vicari
RMReza Mirzazadeh
Reza Mirzazadeh
ANAnna Nilsson
Anna Nilsson
RSReza Shariatgorji
Reza Shariatgorji
PBPatrik Bjärterot
Patrik Bjärterot
JLJoakim Lundeberg
Joakim Lundeberg
We present a spatial omics approach that merges and expands the capabilities of independently performed in situ assays on a single tissue section. Our spatial multimodal analysis combines histology, mass spectrometry imaging, and spatial transcriptomics to facilitate precise measurements of mRNA transcripts and low-molecular weight metabolites across tissue regions. We demonstrate the potential of our method using murine and human brain samples in the context of dopamine and Parkinson’s disease.

27 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
PBPatrik Bjärterot
Patrik Bjärterot
ANAnna Nilsson
Anna Nilsson
RSReza Shariatgorji
Reza Shariatgorji
TVTheodosia Vallianatou
Theodosia Vallianatou
IKIbrahim Kaya
Ibrahim Kaya
PAPer E. Andrén
Per E. Andrén
Here, we introduce Met-ID, a graphical interface software designed to efficiently identify metabolites from MALDI-MSI datasets. Met-ID enables annotation of m/z features from any type of MALDI-MSI experiment, involving either derivatizing or conventional matrices. It utilizes structural information for derivatizing matrices to generate a subset of targets that contain only functional groups specific to the derivatization agent. The software is able to identify multiple derivatization sites on the same molecule, facilitating identification of the derivatized compound. This ability is exemplified by FMP-10, a reactive matrix that assists the covalent charge-tagging of molecules containing phenolic hydroxyl and/or primary or secondary amine groups. Met-ID also permits users to recalibrate data with known m/z ratios, boosting confidence in mass match results. Furthermore, Met-ID includes a database featuring MS2 spectra of numerous chemical standards, consisting of neurotransmitters and metabolites derivatized with FMP-10, alongside peaks for FMP-10 itself, all accessible directly through the software. The MS2 spectral database supports user-uploaded spectra and enables comparison of these spectra with user-provided tissue MS2 spectra for similarity assessment. Although initially installed with basic data, Met-ID is designed to be customizable, encouraging users to tailor the software to their specific needs. While several MSI-oriented software solutions exist, Met-ID stands out as a pioneer in seamlessly combining both MS1 and MS2 functionalities. Developed in alignment with the FAIR Guiding Principles for scientific software, Met-ID is freely available as an open-source tool on GitHub, ensuring wide accessibility and collaboration.